Allogene Therapeutics Revenue and Competitors

Claim your profile

Location

$531.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Allogene Therapeutics's estimated annual revenue is currently $38.4M per year.(i)
  • Allogene Therapeutics received $120.0M in venture funding in September 2018.
  • Allogene Therapeutics's estimated revenue per employee is $101,963
  • Allogene Therapeutics's total funding is $531.8M.
  • Allogene Therapeutics's current valuation is $1.9B. (January 2022}

Employee Data

  • Allogene Therapeutics has 377 Employees.(i)
  • Allogene Therapeutics grew their employee count by 20% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$27.4M146-5%$160MN/A
#2
$3.7M24N/AN/AN/A
#3
$18.1M93-3%$24.1MN/A
#4
$47.1M304-3%N/AN/A
#5
$48.1M28014%$403MN/A
#6
$459.2M206854%$242.6MN/A
#7
$0.9M14133%$6.1MN/A
#8
$14.9M79-12%$140MN/A
#9
$29M187-1%N/AN/A
#10
$3.7M24N/AN/AN/A

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for off-the-shelf use in patients. This approach eliminates the need to create personalized therapy from a patient's own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy currently in Phase 1 development for the treatment of acute lymphoblastic leukemia (ALL). Through its notable partnerships, Allogene leverages pioneering technology platforms, including TALEN® gene editing technology, to progress its portfolio of immuno-oncology therapies. Allogene, with headquarters in San Francisco, California, is a Two River portfolio company formed with one of the largest Series A financings in biotechnology from an investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer, among others. For more information, please visit www.allogene.com, follow @AllogeneTx on Twitter and LinkedIn.

keywords:N/A

$531.8M

Total Funding

377

Number of Employees

$38.4M

Revenue (est)

20%

Employee Growth %

$1.9B

Valuation

N/A

Accelerator

Allogene Therapeutics News

2022-04-20 - Allogene Therapeutics (NASDAQ:ALLO) vs. Halozyme ...

Allogene Therapeutics (NASDAQ:ALLO) vs. Halozyme Therapeutics (NASDAQ:HALO) Financial Contrast. Posted by admin on Apr 20th, 2022.

2022-04-17 - Allogene Therapeutics Unveils Cell Forge 1, a Uniquely ...

SOUTH SAN FRANCISCO, Calif. , April 14, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology...

2022-04-13 - Allogene Therapeutics Publishes Preclinical Data on ALLO ...

Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell...

2021-01-19 - Allogene Therapeutics : J.P. Morgan Conference Presentation - January 2021

The Next Revolution in Cell Therapy Leading Today, Creating Tomorrow 39th Annual J.P. Morgan Healthcare Conference January 2021 Legal Disclaimers To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene ...

2021-01-19 - ALLOGENE THERAPEUTICS, INC. Allogene Therapeutics : J.P. Morgan Conference Presentation - January 2021

The Next Revolution in Cell Therapy Leading Today, Creating Tomorrow 39th Annual J.P. Morgan Healthcare Conference January 2021 Legal Disclaimers To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$154.6M3771%N/A
#2
$63.7M37738%$156.5M
#3
$42.4M377333%$313M
#4
$78.7M37726%N/A
#5
$47.3M3785%N/A

Allogene Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-04-20$411.8MUndisclosedVida VenturesArticle
2018-09-07$120.0MUndisclosedPerceptive AdvisorsArticle